Long Term Extension Study in Patients With Primary Hyperoxaluria

NCT04042402 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria Type 2 (PH2)
Kidney Diseases
Urologic Diseases
Genetic Disease
Primary Hyperoxaluria Type 3 (PH3)

Interventions

DRUG: DCR-PHXC

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company